We also demonstrated the benefit of B4GALNT1 depletion in PD-1-targeted immunotherapy, which enhances the understanding of HCC progression and provides a novel auxiliary strategy for HCC immunotherapy. This evidence concerns the gene B4GALNT1 and hepatocellular carcinoma.